JP2023116503A5 - - Google Patents

Download PDF

Info

Publication number
JP2023116503A5
JP2023116503A5 JP2023085024A JP2023085024A JP2023116503A5 JP 2023116503 A5 JP2023116503 A5 JP 2023116503A5 JP 2023085024 A JP2023085024 A JP 2023085024A JP 2023085024 A JP2023085024 A JP 2023085024A JP 2023116503 A5 JP2023116503 A5 JP 2023116503A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
crystalline form
treatment
btk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023085024A
Other languages
English (en)
Japanese (ja)
Other versions
JP7596441B2 (ja
JP2023116503A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/043937 external-priority patent/WO2020028258A1/en
Application filed filed Critical
Publication of JP2023116503A publication Critical patent/JP2023116503A/ja
Publication of JP2023116503A5 publication Critical patent/JP2023116503A5/ja
Priority to JP2024206520A priority Critical patent/JP2025037966A/ja
Application granted granted Critical
Publication of JP7596441B2 publication Critical patent/JP7596441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023085024A 2018-07-31 2023-05-24 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤 Active JP7596441B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024206520A JP2025037966A (ja) 2018-07-31 2024-11-27 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862712861P 2018-07-31 2018-07-31
US62/712,861 2018-07-31
US201862729855P 2018-09-11 2018-09-11
US62/729,855 2018-09-11
US201862769308P 2018-11-19 2018-11-19
US62/769,308 2018-11-19
PCT/US2019/043937 WO2020028258A1 (en) 2018-07-31 2019-07-29 Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
JP2021505208A JP7286755B2 (ja) 2018-07-31 2019-07-29 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021505208A Division JP7286755B2 (ja) 2018-07-31 2019-07-29 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024206520A Division JP2025037966A (ja) 2018-07-31 2024-11-27 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Publications (3)

Publication Number Publication Date
JP2023116503A JP2023116503A (ja) 2023-08-22
JP2023116503A5 true JP2023116503A5 (enExample) 2024-02-05
JP7596441B2 JP7596441B2 (ja) 2024-12-09

Family

ID=67551747

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021505208A Active JP7286755B2 (ja) 2018-07-31 2019-07-29 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤
JP2023085024A Active JP7596441B2 (ja) 2018-07-31 2023-05-24 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤
JP2024206520A Pending JP2025037966A (ja) 2018-07-31 2024-11-27 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021505208A Active JP7286755B2 (ja) 2018-07-31 2019-07-29 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024206520A Pending JP2025037966A (ja) 2018-07-31 2024-11-27 (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤

Country Status (8)

Country Link
US (3) US12109193B2 (enExample)
EP (1) EP3829543A1 (enExample)
JP (3) JP7286755B2 (enExample)
KR (3) KR102545594B1 (enExample)
CN (3) CN117281803A (enExample)
AU (3) AU2019314302A1 (enExample)
CA (4) CA3224945C (enExample)
WO (1) WO2020028258A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP3981399A4 (en) * 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー, インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
US20230145305A1 (en) * 2020-03-12 2023-05-11 Fochon Biosciences, Ltd. Compounds useful as kinase inhibitors
TWI809489B (zh) 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
EP4291187A4 (en) * 2021-02-15 2025-01-15 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
KR20230171449A (ko) * 2021-05-14 2023-12-20 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 공결정질 형태
CA3229887A1 (en) * 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
IL322630A (en) 2023-02-22 2025-10-01 Assia Chem Ind Ltd Solid forms of pirobrutinib
WO2024179558A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Pirtobrutinib的晶型及其制备方法和用途
WO2024194890A1 (en) * 2023-03-20 2024-09-26 Dr. Reddy’S Laboratories Limited Solid state forms of pirtobrutinib and process for the preparation of intermediate thereof
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib
WO2025083736A1 (en) * 2023-10-20 2025-04-24 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of pirtobrutinib and its intermediates thereof
CN119857081B (zh) * 2025-01-16 2025-10-17 江苏亚邦爱普森药业有限公司 一种乌帕替尼缓释片及其制备方法
CN120591230B (zh) * 2025-07-02 2025-11-25 广东金骏康生物技术有限公司 一种甲基转移酶CicOMT10突变体、制备方法、生物材料和应用

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
IL153375A0 (en) 2000-06-22 2003-07-06 Genentech Inc Agonist anti-trk-c monoclonal antibodies
WO2004074244A2 (en) 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
EA017318B1 (ru) 2005-08-25 2012-11-30 Креабилис Терапеутикс С.П.А. Полимерные конъюгаты индолокарбазола и его производных
WO2007026720A1 (ja) 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
BRPI0709680B8 (pt) 2006-03-27 2021-05-25 Nerviano Medical Sciences Srl derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
AU2008247442B2 (en) 2007-05-04 2013-01-10 Irm Llc Compounds and compositions as c-kit and PDGFR kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
AU2008273889B2 (en) 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
RU2474580C2 (ru) 2007-07-19 2013-02-10 Шеринг Корпорейшн Гетероциклические амидные соединения как ингибиторы протеинкиназ
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
KR20100089851A (ko) 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 trkb 항체의 용도
JP5400791B2 (ja) 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
JP5420568B2 (ja) 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗TrkB抗体
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
EP2282995B1 (en) 2008-05-23 2015-08-26 Novartis AG Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
US8946226B2 (en) 2008-07-29 2015-02-03 Nerviano Medical Sciences S.R.L. Use of CDK inhibitor for the treatment of glioma
US8394802B2 (en) 2008-09-19 2013-03-12 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
JP2012509859A (ja) 2008-11-24 2012-04-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 中皮腫の治療のためのcdk阻害物質
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2435491T3 (es) 2009-10-09 2013-12-19 Incyte Corporation Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
US8772279B2 (en) 2010-01-29 2014-07-08 Nerviano Medical Sciences S.R.L. 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
ES2586588T3 (es) 2011-01-26 2016-10-17 Nerviano Medical Sciences S.R.L. Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa
BR112013018515B1 (pt) 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
RU2606497C2 (ru) 2011-02-24 2017-01-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
JP5976778B2 (ja) 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
JP5970537B2 (ja) 2011-04-19 2016-08-17 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピリミジニル−ピロール
BR112013028733B1 (pt) 2011-05-12 2022-05-10 Nerviano Medical Sciences S.R.L Derivados de indazol substituiídos ativos como inibidores de quinase
SG10201913053QA (en) 2011-05-13 2020-03-30 Array Biopharma Inc Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
JP6016915B2 (ja) 2011-07-28 2016-10-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール
ES2660265T3 (es) 2011-10-07 2018-03-21 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona 4-alquil-sustituidos como inhibidores de cinasa
ES2639064T3 (es) 2011-10-07 2017-10-25 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
JP2014533286A (ja) 2011-11-14 2014-12-11 テサロ, インコーポレイテッド 特定のチロシンキナーゼの調節
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6096219B2 (ja) 2012-01-13 2017-03-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物
US9242977B2 (en) 2012-04-26 2016-01-26 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
ES2751944T3 (es) 2012-05-23 2020-04-02 Nerviano Medical Sciences Srl Proceso para la preparación de N-[5-(3,5-difluoro-bencil)-1H-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
BR112015002152B1 (pt) 2012-08-02 2021-04-27 Nerviano Medical Sciences S.R.L. Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
EP3680238A1 (en) 2012-10-04 2020-07-15 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2014072220A1 (en) 2012-11-07 2014-05-15 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
SMT201800169T1 (it) 2012-11-13 2018-05-02 Array Biopharma Inc Composti di n-pirrolidinile, n'-pirazolile-urea, tiourea, guanidina e cianoguanidina come inibitore di chinasi trka
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RS55593B1 (sr) 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
MX353336B (es) 2013-02-19 2018-01-09 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
EP2970334B1 (en) 2013-03-15 2018-05-23 Biogen MA Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9682083B2 (en) 2013-05-14 2017-06-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
EP3016953A4 (en) 2013-07-02 2017-03-01 Pharmacyclics, LLC Purinone compounds as kinase inhibitors
EP3027654B1 (en) 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
EP3628749A1 (en) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
RS58361B1 (sr) 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
CN104311573B (zh) 2013-09-18 2017-12-15 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
SG11201602070TA (en) 2013-09-30 2016-04-28 Beijing Synercare Pharma Tech Co Ltd Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9321757B2 (en) 2013-11-08 2016-04-26 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
ES2678021T3 (es) 2013-12-11 2018-08-08 Biogen Ma Inc. Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
LT3636649T (lt) 2014-01-24 2024-04-10 Turning Point Therapeutics, Inc. Diarilo makrociklai kaip proteinkinazių moduliatoriai
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ros1突變癌細胞之分子
EP3132054B1 (en) 2014-04-18 2021-06-30 Blueprint Medicines Corporation Met fusions
EP3132056B1 (en) 2014-04-18 2021-11-24 Blueprint Medicines Corporation Pik3ca fusions
EP3154959B1 (en) 2014-05-15 2019-07-10 Array Biopharma, Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3155131B1 (en) 2014-06-10 2020-02-12 Blueprint Medicines Corporation Raf1 fusions
WO2015191667A1 (en) 2014-06-10 2015-12-17 Blueprint Medicines Corporation Pkn1 fusions
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
EP3169804B3 (en) 2014-07-17 2019-09-18 Blueprint Medicines Corporation Fgr fusions
EP3169808B1 (en) 2014-07-17 2019-05-22 Blueprint Medicines Corporation Trio:tert fusion in cancer
EP3169809B1 (en) 2014-07-17 2020-04-29 Blueprint Medicines Corporation Prkc fusions
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CA2955747A1 (en) * 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
AU2015304438B2 (en) 2014-08-18 2019-06-20 Ono Pharmaceutical Co., Ltd. Acid-addition salt of Trk-inhibiting compound
EP3200787B1 (en) 2014-09-30 2019-09-04 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2016050921A1 (en) 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
EP3461821B1 (en) 2014-10-24 2020-05-13 Bristol-Myers Squibb Company Indole carboxamide compounds useful as kinase inhibitors
SG11201703186RA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
EA039885B1 (ru) 2014-11-14 2022-03-23 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
PT3699181T (pt) 2014-11-16 2023-04-05 Array Biopharma Inc Forma cristalina de hidrogenossulfato de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
EP3221700B1 (en) 2014-11-18 2022-06-22 Blueprint Medicines Corporation Prkacb fusions
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
KR20170109546A (ko) 2015-02-05 2017-09-29 메르크 파텐트 게엠베하 Irak1/4 억제제로서의 매크로시클릭 화합물 및 이들의 용도
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2016161570A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Azacarbazole btk inhibitors
PE20180118A1 (es) 2015-04-22 2018-01-18 Rigel Pharmaceuticals Inc Compuestos de pirazol y metodo para elaborar y usar los compuestos
EP3288558B1 (en) 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA3025813A1 (en) 2015-05-27 2016-12-01 Gb005, Inc. Inhibitors of the tec kinase enzyme family
KR102666352B1 (ko) 2015-06-03 2024-05-17 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
JP7083750B2 (ja) 2015-09-18 2022-06-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Irak阻害剤としてのヘテロアリール化合物及びその使用
US20170035881A1 (en) 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
MX380907B (es) * 2015-12-16 2025-03-12 Loxo Oncology Inc Compuestos útiles como inhibidores de cinasa.
DK3390390T3 (da) 2015-12-16 2021-12-06 Boehringer Ingelheim Int Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
CH713411B1 (fr) 2015-12-18 2021-03-31 Service Regional Vaudois De Transfusion Sanguine Test de contrôle de qualité pour verifier l'exécution des traitements d'inanctivation des pathogènes et des cellules ciblées dans le sang, les produits dérivés du sang et les produits cosmétiques.
WO2017134685A2 (en) 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
JP7562256B2 (ja) 2016-08-15 2024-10-07 パデュー リサーチ ファウンデイション 4位置換アミノイソキノリン誘導体
WO2018035080A1 (en) 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
CA2939286A1 (en) 2016-08-17 2018-02-17 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
SG11201901197PA (en) 2016-08-24 2019-03-28 Arqule Inc Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2018049127A1 (en) 2016-09-08 2018-03-15 Sabila Biosciences Llc 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions
KR102686957B1 (ko) 2016-11-08 2024-07-22 주식회사 대웅제약 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
JOP20190113A1 (ar) 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
CN108101905A (zh) 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
CN106831789A (zh) 2016-12-21 2017-06-13 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂
UY37559A (es) 2017-01-06 2018-05-31 Pharmacyclics Llc Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー, インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
TWI809489B (zh) 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體

Similar Documents

Publication Publication Date Title
JP2023116503A5 (enExample)
EP2695881B1 (en) Guanidine compound
TW434229B (en) Biphenyl derivatives
TW419471B (en) Morpholine derivatives useful as tachykinin receptor antagonists, preparation thereof and pharmaceutical composition containing same
JP6453231B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
JP2017526711A5 (enExample)
US8802679B2 (en) Glycine compound
TW200838511A (en) Novel pharmaceutical compounds
CN113474339B (zh) 作为malt1抑制剂的化合物的结晶形式
JPH08510736A (ja) 炎症治療用置換オキサゾリル化合物
JP2004529874A5 (enExample)
SG187176A1 (en) Agonists of gpr40
CA2950072A1 (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
US10995072B2 (en) Inhibitors of protease-activated receptor-2
TW200836740A (en) Novel 2, 4-dianilinopyrimidine derivatives, their preparation, as medicaments, pharmaceutical compositions and in particular as IKK inhibitors
TW426674B (en) New 2-(3H)-oxazolone derivatives
TWI233358B (en) Preventive or recurrence-suppressive agents for liver cancer
AU4386593A (en) 5'-indolinyl oxazolidinones useful against (mycobacterium tuberculosis)
CN101160307A (zh) 用于治疗cinv和ibs-d的苯并噁唑甲酰胺
US9079876B2 (en) Imidazole derivatives and preparation method and use thereof
JP2018024683A5 (enExample)
CN106543106B (zh) N-苄基苯甲酰胺类化合物及其制备方法
TWI254046B (en) Novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and medicaments containing these compounds
JPS5951262A (ja) 異項環基含有化合物
JPS5939892A (ja) 新規なピリミドン誘導体及びその製法